# Are GLP-1 Drugs Bad for Your Liver? The Evidence Says Better | This GLP A meta-analysis of eleven trials in type 2 diabetes and fatty liver reported ALT and HbA1c effects with separate certainty grades — and declined to rank the drug classes. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/are-glp1-drugs-bad-for-your-liver Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Are GLP-1 Drugs Bad for Your Liver? The Evidence Says Better Eleven trials found liver enzymes falling on these drugs. The authors then refused to rank the drug classes, and said they could not compare safety at all. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Effect, and how much to believe it · SGLT2 inhibitor · ALT · −7.56 U/L · moderate certainty · SGLT2 inhibitor · HbA1c · −0.09% · moderate certainty · GLP-1 agonist · ALT · −6.71 U/L · moderate certainty · GLP-1 agonist · HbA1c · −0.48% · low certainty · Eleven trials, 642 analyzed — and no class ranking offered **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Eleven randomized trials, 692 people randomized and 642 analyzed, in adults with type 2 diabetes and fatty liver disease. - Adding a GLP-1 lowered ALT by 6.71 U/L, 95% CI −11.53 to −1.89, at moderate certainty. - It lowered HbA1c by 0.48 percentage points, 95% CI −0.83 to −0.14 — at low certainty. - The authors state the evidence does not support ranking the drug classes against each other. - They also state that comparative safety could not be assessed, because adverse-event reporting was incomplete. On the measured evidence they look good for it rather than bad. Pooled across eleven randomized trials in adults with type 2 diabetes and fatty liver disease, adding a GLP-1 lowered ALT by 6.71 U/L at moderate certainty. HbA1c fell by 0.48 percentage points, graded low certainty — the two numbers do not carry equal weight, and the review says so. Liver cancer is the outcome people mean when they ask this, and it has been measured twice with the same shape of answer. A target trial emulation found five-year hepatocellular carcinoma risk LOWER on a GLP-1 than on every comparator, by 0.37 to 0.52 percentage points [\[2\]](https://thisglp.com/research/are-glp1-drugs-bad-for-your-liver#ref-2). Those differences stay under 0.6 points because the cancer is rare, which is the reading in [half a percentage point over five years](https://thisglp.com/research/glp1-liver-cancer-absolute-risk). A second study found liver cancer slightly HIGHER and dismissed it for being negligible, with a risk difference rounding to zero [\[3\]](https://thisglp.com/research/are-glp1-drugs-bad-for-your-liver#ref-3). That reasoning is right, and [applied to the same study’s benefits it makes those real and small rather than transformative](https://thisglp.com/research/glp1-liver-cancer-signal-dismissed). Most reviews end by telling you which option is best. This one ends by explaining why it will not, and the explanation is more useful than a ranking would have been. ## What was measured Eleven randomized trials in Asian study settings, in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease, all adding a study drug to comparable background glucose-lowering therapy. [\[1\]](https://thisglp.com/research/are-glp1-drugs-bad-for-your-liver#ref-1) 692 participants were randomized into eligible comparisons and 642 entered the coprimary analyses. The coprimary outcomes were change in ALT, a liver enzyme, and change in HbA1c. Adding a GLP-1 reduced ALT by 6.71 U/L, 95% CI −11.53 to −1.89, graded moderate certainty. It reduced HbA1c by 0.48 percentage points, 95% CI −0.83 to −0.14, graded low certainty. Adding an SGLT2 inhibitor reduced ALT by 7.56 U/L, 95% CI −11.24 to −3.88, at moderate certainty, with little or no clinically important further effect on HbA1c. ALT is a blood test, not a liver Alanine aminotransferase is an enzyme that leaks from damaged liver cells, so it tracks injury loosely and imperfectly. A fall of about 7 units is a change in a number. Whether it corresponds to less scarring, fewer people progressing to cirrhosis, or anybody living longer is what short trials with surrogate endpoints are least able to answer. This is also the same disease where an approved treatment [is defined by a fibrosis stage](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease), not by an enzyme. ## Where the endpoint was the liver itself A separate 2025 meta-analysis went past the enzyme to the tissue, pooling 13 phase 2 and phase 3 trials with 1,811 participants, four of which diagnosed the disease by biopsy and nine by MRI [\[4\]](https://thisglp.com/research/are-glp1-drugs-bad-for-your-liver#ref-4). In people with steatohepatitis and moderate to advanced fibrosis, GLP-1 drugs beat placebo at resolving the inflammation, an odds ratio of 3.48 across three trials. They also beat it at improving fibrosis, at 1.79, and the authors single out semaglutide 2.4 mg a week among the drugs tested. The same paper marks where the benefit stopped. In the one trial of people whose disease had already reached compensated cirrhosis, semaglutide did not resolve the steatohepatitis or improve fibrosis against placebo, and the authors say the effect on liver-related events over the long term still needs study. ## Two grades for one drug Notice that the GLP-1 estimates carry different certainty ratings. Moderate for the liver enzyme, low for the blood sugar measure. That is not an inconsistency; it reflects how many trials contributed to each comparison, how consistent they were, and how precise the pooled estimate is. A summary that reported both numbers without both grades would treat them as equally settled. They are not, and the authors went to the trouble of grading them separately — which is the sort of distinction [a pooled figure usually hides](https://thisglp.com/research/glp1-weight-loss-pooled-average). ## The three refusals First, no class ranking. The authors state the available evidence does not support ranking SGLT2 inhibitors, GLP-1 agonists and pioglitazone against one another — several comparisons rested on sparse evidence, and the two classes were not tested head to head. Second, no claim about durability or clinical significance. Follow-up was short and the endpoints were surrogates, so the paper says both of those remain uncertain rather than projecting forward. Third, and most striking: comparative safety could not be assessed reliably, because adverse-event reporting across the trials was heterogeneous and incomplete. Eleven randomized trials, and the authors could not compare how safe the drugs were relative to each other. That is a statement about the literature rather than about the drugs, and it is the kind of thing that never survives into a summary. ## Why a refusal is worth reading Because the demand for rankings is what produces bad ones. A reader wants to know which drug to take, and a marketer wants to say theirs. A review that declines to answer is doing the harder and more honest thing — [a comparison nobody ran](https://thisglp.com/research/do-glp1-drugs-cause-gout) cannot be reconstructed from two separate ones. The practical version for anybody reading a claim about these drugs and the liver: ask which endpoint moved, how certain the authors were, and whether they compared the drug to the alternative or only to background care. Almost nothing published by a seller answers any of the three, which [the disclosure scorecard](https://thisglp.com/tools/what-sellers-publish) measures from the other end. ## Frequently asked Do these drugs improve fatty liver disease? They lowered ALT, a liver enzyme, by about 6.71 U/L at moderate certainty in these trials. Whether that corresponds to less scarring or better long-term outcomes is what the authors say remains uncertain. Do GLP-1 drugs reverse liver scarring? In people with steatohepatitis and moderate to advanced fibrosis, a meta-analysis of randomized trials found fibrosis improved more often than on placebo, at an odds ratio of 1.79. In the one trial of compensated cirrhosis, semaglutide did not improve fibrosis. Which drug class is best for this? The authors decline to say, stating that the available evidence does not support a treatment-class ranking. The classes were not compared head to head and several comparisons rested on sparse evidence. Why do the two GLP-1 results have different certainty grades? Moderate for ALT and low for HbA1c. Certainty reflects how many trials contributed, how consistent they were and how precise the estimate is, so two findings from the same review can deserve different confidence. What about side effects? The review could not assess comparative safety, because adverse-event reporting across the eleven trials was heterogeneous and incomplete. ## Sources 1. \[1\] Zheng H, et al. (2026). Incremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis Frontiers in Endocrinology. [PMID 42745769](https://pubmed.ncbi.nlm.nih.gov/42745769/) 2. \[2\] Hernández-Pérez JG, et al. (2026). Comparative risk of hepatocellular carcinoma and mortality among initiators of GLP-1 receptor agonists versus other glucose-lowering therapies: a target trial emulation Hepatology International. [PMID 42584814](https://pubmed.ncbi.nlm.nih.gov/42584814/) 3. \[3\] Khan SA, et al. (2026). Clinical outcomes associated with GLP-1 receptor agonist use in metabolic dysfunction-associated steatohepatitis: A multinational cohort study Medicine (Baltimore). [PMID 42736811](https://pubmed.ncbi.nlm.nih.gov/42736811/) 4. \[4\] Mantovani A, et al. (2025). Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials Liver International. [PMID 40736113](https://pubmed.ncbi.nlm.nih.gov/40736113/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)